© 2020 MJH Life Sciences and AJMC. All rights reserved.
© 2020 MJH Life Sciences™ and Clinical Care Targeted Communications, LLC. All rights reserved.
March 10, 2020
This study assesses the cost-effectiveness of adding a sodium-glucose cotransporter 2 inhibitor versus switching to a glucagon-like peptide-1 receptor agonist in patients with diabetes on metformin and a dipeptidyl peptidase-4 inhibitor.
May 07, 2018
Formulary restrictions on brand name noninsulin antihyperglycemic drugs have little impact on treatment intensification patterns among low-income patients with diabetes in Medicare Part D.